Technological advances such as those that allow the delivery of an adequate dialysis dose to a larger percentage of patients, minimization of peritoneal membrane damage with more biocompatible solutions, and lower peritonitis rates will undoubtedly improve retention of patients on peritoneal dialysis (PD) for longer periods. Currently, only 15% of the world dialysis population is managed by PD. Peritoneal dialysis has many advantages over hemodialysis, and if end-stage renal disease (ESRD) patients are fully informed about them, the proportion of patients who would prefer this treatment would rise to 25% – 30%. An integrated approach to the treatment of ESRD could start with PD in a large percentage of patients, especially those who will receive a kidney transplant within 2 – 3 years. With the present epidemic of ESRD, this approach could lead to a significant saving, relieve the pressure on dialysis units, and allow a larger number of ESRD patients to be treated.
ShettyA., OreopoulosD.G.Peritoneal dialysis: Its indications and contraindications.Dialysis and Transplantation2000; 29(2): 71–7.
2.
Canada-USA (CANUSA) Peritoneal Dialysis Study Group.Adequacy of dialysis and nutrition in continuous ambulatory peritoneal dialysis: Association with clinical outcomes.J Am Soc Nephrol1996; 7: 198–207.
3.
DaviesS.J., PhillipsL., GriffithsA.M., RussiliL.H., NaishP.F., RusselG.I.What really happens to people on long-term peritoneal dialysis?Kidney Int1998; 54: 2207–17.
4.
MaiorcaR., VoneshE., CavalliP.L., De VecchiA., GiangrandeA., La GrecaG.A multi-center, selection adjusted comparison of patient and technique survivals on CAPD and hemodialysis.Perit Dial Int1991; 11: 118–27.
5.
BloembergenW.E., PortK.F., MaugerA., WolfeR.A.A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis.J Am Soc Nephrol1995; 6: 177–83.
6.
FentonS.S.A., SchaubelD.E., DesmeulesW., MorrisonS.I., MaoY., CoplestonP.Hemodialysis versus peritoneal dialysis: A comparison of adjusted mortality rates.Am J Kidney Dis1997; 30: 334–42.
7.
VoneshE.F., MoranJ.Mortality in end-stage renal disease: A reassessment of differences between patients treated with hemodialysis and peritoneal dialysis.J Am Soc Nephrol1999; 10: 354–65.
8.
CollinsA.J., HaoW., HongX., EbbenJ.R., EversonS.E.Mortality risks of peritoneal dialysis and hemodialysis.Am J Kidney Dis1999; 34: 1065–74.
9.
MurphyS.W., FoleyR.N., BarrettB.N., KentG.M., MorganJ., BarréP.Comparative mortality of hemodialysis and peritoneal dialysis in Canada.Kidney Int2000; 57: 1720–6.
10.
TannaM.M., VoneshE.F., KorbetS.M.Patient survival among incident peritoneal dialysis and hemodialysis patients in an urban setting.Am J Kidney Dis2000; 36: 1175–82.
11.
SchaubelD.F., FentonS.A.Trends in mortality on peritoneal dialysis: Canada 1981–1997.J Am Soc Nephrol2000; 11: 126–33.
12.
FallerB., LameireN.Evolution of clinical parameters and peritoneal function in a cohort of CAPD patients followed over 7 years.Nephrol Dial Transplant1994; 9: 280–6.
13.
LupoA., CancariniG., CatizoneL., CocchiR., De VecchiA., ViglinoG.Comparison of survival in CAPD and hemodialysis: A multi-center study.Adv Perit Dial1992; 8: 136–40.
14.
DaviesS.J., PhillipsL., RussellG.I.Peritoneal solute transport predicts survival on CAPD independently of residual renal function.Nephrol Dial Transplant1998; 13: 962–8.
15.
KawaguchiY., HasegawaT., NakayamaM., KuboH., ShigematsuT.Issues affecting the longevity of the continuous peritoneal dialysis therapy.Kidney Int1997; 52(Suppl 62): S105–7.
16.
LameireN.H., VanholderR., VeytD., LambertM., RingoirS.A longitudinal five year survey of urea kinetic parameters in CAPD patients.Kidney Int1992; 42: 426–32.
17.
De VecchiA.F., MaccarioM., ScalamognaA., CastenovoC., PonticelliC.Nine patients treated for more than 10 years with continuous ambulatory peritoneal dialysis.Am J Nephrol1996; 16: 455–61.
18.
Rodriguez–CarmonaA., FalconT.G., Perez FontanM., BouzaP., AdevaM., RiveraC.F.Survival on chronic peritoneal dialysis: Have results improved in the 1990s?Perit Dial Int1996; 16(Suppl 1): 410–13.
19.
GokalR., MistryC.D., PeersE., and the MIDAS Study Group. A United Kingdom multicenter study of icodextrin in continuous ambulatory peritoneal dialysis.Perit Dial Int1994; 14(Suppl 1): S22–7.
20.
SimmonsR.G., AndersonC.R., AbressL.K.Quality of life and rehabilitation differences among four ESRD therapy groups.Scand J Urol Nephrol Suppl1990; 131: 7–22.
21.
StoutJ.P., AuerJ., KinseyJ.Sexual and marital relationships and dialysis — patient's viewpoint.Perit Dial Bull1987; 7: 92–101.
22.
MorrisP.L., JonesB.Transplantation versus dialysis: A study of quality of life.Transplant Proc1988; 20: 23–6.
23.
NissensonA.R., MaidaC.A., KatzA.H., WolcottD.L., LandsverkJ., StraussG.Psychosocial adaptation of CAPD and centre hemodialysis patients. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G. (eds). Advances in continuous ambulatory peritoneal dialysis.Toronto: Peritoneal Dialysis Bulletin, Inc., 1986; 2: 42–56.
24.
MerkusM.P., JagerK.J., DekkerF.W., BoeschotenE.W., StevensP., KredietR.T., and the NECOSAD Study Group. Quality of life in patients on chronic dialysis: Self-assessment 3 months after the start of treatment.Am J Kidney Dis1997; 29: 584–92.
25.
MercusM., JagerK., DekkerF., De HaanR., BoeschotenE., KredietR.Quality of life over time in dialysis: The Netherlands Cooperative Study on the Adequacy of Dialysis.Kidney Int1999; 56: 720–8.
26.
McHorneyC.A., WareJ.E., RaczekA.E.The MOS 36-item Shortform Health Survey (SF-36). II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.Med Care1993; 31: 247–63.
27.
GarrattA.M., RutaD.A., AbdallaM.I., BuckinghamJ.K., RussellI.T.The SF-36 Health Survey Questionnaire: An outcome measure suitable for routine use within the NHS?BMJ1993; 306: 1437–40.
28.
United States Renal Data System.USRDS 1998 annual data report.Bethesda, MD: The National Institutes of Health and National Institute of Diabetics and Digestive and Kidney Diseases, 1998.
29.
BrunoriG., CameriniC., CancariniG., ManiliL., SandriniE., MonilliE.Hospitalization: CAPD versus hemodialysis and transplant.Adv Perit Dial1992; 8: 71–4.
30.
Excerpts from United States Renal Data System 1996 annual data report: Hospitalization.Am J Kidney Dis1996; 28(Suppl 2): S114–26.
CollinsA., HaoW., LiS., EbbenJ., MaJ.Hospitalization risk in CAPD/CCPD versus hemodialysis (HD) patients by interval Poisson regression (Abstract).J Am Soc Nephrol1999; 10: 1208A.
33.
CollinsA., HaoW., EbbenJ., MaJ.Cardiac hospitalization risk in CAPD/CCPD versus hemodialysis patients (Abstract).J Am Soc Nephrol1999; 10: 1205A.
34.
RottembourgJ.Residual renal function and recovery of renal function in patients treated by CAPD.Kidney Int1993; 43(Suppl 40): S106–10.
35.
LysaghtM.J., VoneshE.F., GotchF., IbelsL., KeenM., LindholmB.The influence of dialysis treatment modality on the decline of remaining renal function.ASAIO Trans1991; 37: 598–604.
36.
NolphK.D.Is residual renal function better preserved with CAPD than with hemodialysis?Am Kidney Fund Nephrol Lett1990; 7: 1–7.
37.
LysaghtM.Preservation of residual function in maintenance dialysis patients.Perit Dial Int1996; 16: 126–7.
38.
NiwaT., IseM.Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis.J Lab Clin Med1994; 124: 96–104.
39.
ChurchillD.N., TaylorD.W., KeshaviahP.Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcome.J Am Soc Nephrol1996; 7: 198–207.
40.
HeimbürgerO., WaniewskiJ., WerynskiA., TranæusA., LindholmB.Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity.Kidney Int1990; 38: 495–506.
41.
ChandraM., ClemonsG.K., McVicarM., WilkesB., MosseyR.T.Serum erythropoietin levels and hematocrit in end-stage renal disease: Influence of the mode of therapy.Am J Kidney Dis1988; 12: 208–13.
42.
TielemansC., DratwaM., BergmannP., GoldmanM., FlamionB., CollartF.Continuous ambulatory peritoneal dialysis: A lesser risk of amyloidosis?Nephrol Dial Transplant1988; 3: 291–4.
NiwaT., VasawaT., KodamaT., UeharaV., MaedaK., YamadaK.Efficient removal of albumin-bound furancarbolic acid, an inhibitor of erythropoiesis by CAPD.Nephron1990; 56: 241–5.
45.
LameireN.Cardiovascular risk factors and blood pressure control in continuous ambulatory peritoneal dialysis.Perit Dial Int1993; 13(Suppl 2): S394–5.
46.
MaiorcaR., CancariniG.C., BrunoriG., CameriniC., ManiliL.Morbidity and mortality of CAPD and hemodialysis.Kidney Int1993; 43(Suppl 40): S5–15.
47.
HutingJ., AlpertM.A.Progression of left ventricular hypertrophy in end-stage renal disease treated by continuous ambulatory peritoneal dialysis depends on hypertension and hypercirculation.Clin Cardiol1992; 15: 190–6.
48.
EisensteinM., PrichardS., BarréP., PattenR., HutchinsonT., SnidermanA.Left ventricular hypertrophy in end-stage renal disease patients on peritoneal dialysis.Am J Cardiol1987; 60: 418–19.
49.
FranklinJ.O., AlpertM.A., TwardowskiZ.J., KhannaR., NolphK.D., MorganR.J.Effect of increasing intraabdominal pressure and volume on left ventricular function in continuous ambulatory peritoneal dialysis (CAPD).Am J Kidney Dis1988; 12: 291–8.
50.
HutingJ., KramerW., ReitingerJ., KuhnK., SchutterleG., WizemannV.Abdominal diastolic left ventricular filling by pulsed Doppler echocardiography in patients in continuous ambulatory peritoneal dialysis.Clin Nephrol1991; 36: 21–8.
51.
DahanM., SiohanP., VironB., MichelC., PailloleC., GourgonR.Relationship between left ventricular hypertrophy, myocardial contractility, and load conditions in hemodialysis patients. An echocardiographic study.Am J Kidney Dis1997; 30: 780–5.
AvramM.M., SreedharaR., PatelN., ChattopadhyayJ., ThuT., FeinP.Is an elevated level of serum lipoprotein(a) a risk factor for cardiovascular disease in CAPD patients?Adv Perit Dial1996; 12: 266–71.
54.
RosengrenA., Wilhelmsen L ErikssonE., RisbergB., WedelH.Lipoprotein (a) and coronary heart disease: A prospective case-control study in a general population sample of middle aged men.BMJ1990; 301: 1248–51.
55.
KronenbergF., KöningP., NeyerU., AuingerM., PrisbasningA., LanfU.Multicenter study of lipoprotein (a) and apolipoprotein phenotypes in patients with end stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis.J Am Soc Nephrol1995; 6: 110–20.
56.
StenvinkelP., HeimbürgerO., TuckC.H., BerglundL.Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure.Kidney Int1999; 53: 1336–42.
57.
JonesM.R., GehrT.W., BurkartJ.M., HamburgerR.J., KrausA.P., PirainoB.M.Replacement of amino acid and protein losses with 1.1% amino acid peritoneal dialysis solution.Perit Dial Int1998; 18: 210–16.
58.
ThodisE., BhaskaranS., PassadakisP., BargmanJ.M., VasS.I., OreopoulosD.G.Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter site.Perit Dial Int1998; 18: 261–70.
59.
KoppleJ.D., BernardD., MessanaJ., SwartzR., BergströmJ., LindholmB.Treatment of malnourished CAPD patients with an amino acid based dialysate.Kidney Int1995; 47: 1148–57.
60.
BergströmJ., LindholmB.Malnutrition, cardiac disease and mortality: An integrated point of view.Am J Kidney Dis1998; 32: 834–41.
61.
MazzuchiN., Fernandez–CeanJ.M., CarbonellE.Criteria for selection of ESRD treatment modalities.Kidney Int2000; 57(Suppl 74): 136–43.
62.
TeraokaS., TomaH., NiheiH., OkaK., BabazonoT., IshikawaI.Current status of renal replacement therapy in Japan.Am J Kidney Dis1995; 25: 151–64.
63.
AgodoaL.Y., EggersP.W.Renal replacement therapy in the United States: Data from the United States Renal Data System.Am J Kidney Dis1995; 25: 119–33.
Van BiesenW., VanholderR., LameireN.The role of peritoneal dialysis as the first line renal replacement modality.Perit Dial Int2000; 20: 375–83.
66.
BleyerA., BurkartJ., RusselG., AdamsP.Dialysis modality and delayed graft function after cadaveric renal transplantation.J Am Soc Nephrol1999; 10: 154–9.
67.
IsmailN., HakimR.M., HeldermanJ.H.Renal replacement therapies in the elderly: Part II. Renal transplantation.Am J Kidney Dis1994; 23: 1–15.
68.
Van BiesenW., VanholderR., Van LooA., Van Der VennetM., LameireN.Peritoneal dialysis favorably influences recovery of renal function after transplantation.Transplantation2000; 69: 508–14.
69.
PereiraB.J.G., LeveyA.S.Hepatitis C virus infection in dialysis and renal transplantation.Kidney Int1997; 51: 981–99.
70.
CendorogloM., DraibeS.A., SilvaA., FerrazM., GranatoC., PereiraC.Incidence of and risk factors for hepatitis B virus infection among hemodialysis and CAPD patients: Evidence for environmental transmission.Nephrol Dial Transplant1995; 10: 240–6.
71.
SelgasR., Martinez–ZapicoR., BajoM.A., RomeroJ.R., MunozJ., RinonC.Prevalence of hepatitis C antibodies (HCV) in a dialysis population at one center.Perit Dial Int1992; 12: 28–30.
72.
HuangC.C., WuM.S., LinD.Y., LiawY.F.The prevalence of hepatitis C virus antibodies in patients treated with continuous ambulatory peritoneal dialysis.Perit Dial Int1992; 12: 31–3.
73.
BrugnanoR., FrancisciD., QuintalianiG., GaburriM., NoriG., VerduraC.Antibodies against hepatitis C virus in hemodialysis patients in the central Italian region of Umbria: Evaluation of some risk factors.Nephron1992; 61: 263–5.
MarcusR., FaveroM.S., BanerjeeS., SolomonS.L., BellD.M., JarvisW.R.Prevalence and incidence of human immunodeficiency virus among patients undergoing long-term hemodialysis. The Cooperative Dialysis Study Group.Am J Med1991; 90: 614–19.
76.
TokarsJ.I., AlterM.J., FaveroM.S., MoyerL.A., BlondL.E.National surveillance of dialysis associated diseases in the United States, 1993.ASAIO J1996; 42: 219–29.
77.
KimmelP.L., UmanaW.O., SimmensS.J., WatsonJ., BoschJ.P.Continuous ambulatory peritoneal dialysis and survival of HIV infected patients with end-stage renal disease.Kidney Int1993; 44: 373–8.
78.
SchoenfeldP., RodriguezR., MendelsonM.Patients with HIV infection and end-stage renal disease.Adv Ren Replace Ther1996; 3: 287–92.
79.
PrichardS.Workshop on comparisons of CAPD with hemodialysis and transplantation. The cost of dialysis. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in CAPD.Toronto: Peritoneal Dialysis Bulletin, 1988; 4: 66–9.
80.
PommerW., BreuM., BraunerM., NeubauerG., WeidermannM.E.Treatment costs for peritoneal and hemodialysis therapy in Germany: Results from a prospective cost-comparison analysis approach (Abstract).Perit Dial Int2000; 20: 143.
81.
RubleeD., PeetersP., JosephA., UstP.Analysis and interpretation of cost data in dialysis: Review of Western European literature (Abstract).Perit Dial Int2000; 20: 130.
82.
WestmanJ., GeorgeS., ScheelP.J.Jr., McMurrayS.D., PulliamJ.Options for dialysis providers in a global capitated environment.Nephrol News Issues1996; 10(9): 26–32.
83.
DratwaM.Aspects financiers de la dialyse peritoneale versus hemodialyse. Proceedings of the Symposium on Peritoneal Dialysis, La Bresse 1997. Antwerp: Fresenius MC, Chpt 6.
84.
EvansR.W., ManninenD.L., GarrisonL.P.The quality of life of patients with end-stage renal failure.N Engl J Med1985; 312: 553–9.
85.
Van BiesenW., DequidtC., VijtD., VanholderR., LameireN.Analysis of the reasons for transfer between hemodialysis and peritoneal dialysis and their effect on survivals.Adv Perit Dial1998; 14: 92–4.
86.
Van BiesenW., VanholderC.R., VeysN., DhondtA., LameireH.N.An evaluation of an integrative care approach for end-stage renal disease patients.J Am Soc Nephrol2000; 11: 116–25.
87.
WoodrowG., JurneyJ.H., BrownjohnA.M.Technique failure in peritoneal dialysis and its impact on patient survival.Perit Dial Int1997; 17: 360–4.
